论文部分内容阅读
目的:评价替吉奥与紫杉醇对晚期老年胃癌患者病灶的缓解作用及其安全性。方法:选取2013年1月—2015年1月收治的晚期老年胃癌患者50例,并将其随机分成A组29例和B组21例;A组患者给予替吉奥与紫杉醇治疗,B组患者给予使用FP方案治疗;比较A组和B组患者治疗后的最近治疗效果、生活质量改善情况、不良反应发生率以及1年内存活率差异。结果:A组患者治疗后的最近疗效、生活质量改善情况、不良反应的发生率率以及1年存活状况明显好于B组(P<0.05);两组患者治疗后的最近治疗效果和存活率经比较其差异无统计学意义(P>0.05)。结论:采用替吉奥与紫杉醇治疗晚期老年胃癌患者的疗效较显著,安全可靠,不良反应较少。
OBJECTIVE: To evaluate the relief and safety of tegaserod and paclitaxel in patients with advanced gastric cancer. Methods: Fifty patients with advanced gastric cancer who were admitted to our hospital from January 2013 to January 2015 were selected and randomly divided into group A (n = 29) and group B (n = 21). Patients in group A received treatment with tegaserod and paclitaxel, and patients in group B The patients were treated with FP regimen. The treatment effect, quality of life, incidence of adverse reactions and the difference of survival rate within one year after treatment were compared between groups A and B. Results: The recent curative effect, quality of life improvement, adverse reaction rate and 1-year survival status of patients in group A were significantly better than those in group B (P <0.05). The recent treatment and survival rates of patients in both groups The difference was not statistically significant (P> 0.05). Conclusion: The efficacy of tirgil and paclitaxel in the treatment of advanced gastric cancer patients is more obvious, safe and reliable, with fewer adverse reactions.